Business Description
![Biocure Technology Inc Biocure Technology Inc logo](https://static.gurufocus.com/logos/0C000018NQ.png?14)
Biocure Technology Inc
NAICS : 325412
SIC : 3741
ISIN : CA09075T1075
Compare
Compare
Traded in other countries / regions
CURE.Canada1WH.GermanyBICTF.USA IPO Date
2018-04-30Description
Biocure Technology Inc is a South Korean-based Bio-Pharmaceutical company specializing in the development and potential commercialization of biosimilar pharmaceutical products. It Developing Biosimilars and CAR-T Cell pharmaceuticals. Its products are CAR-T Cell Therapy, Interferon Beta, Ranibizumab, and PEG-Filgrastim.
Financial Strength
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.09 | |||||
Equity-to-Asset | 0.8 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.03 | |||||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 17 | |||||
3-Year EPS without NRI Growth Rate | 18.1 | |||||
3-Year FCF Growth Rate | 46.4 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
12-1 Month Momentum % | 363.58 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.04 | |||||
Quick Ratio | 0.04 | |||||
Cash Ratio | 0.01 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 2 | |||||
Shareholder Yield % | 80.39 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -122.27 | |||||
ROA % | -58.19 | |||||
ROIC % | -34.89 | |||||
ROCE % | -113.01 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio without NRI | 3 | |||||
PEG Ratio | 0.09 | |||||
PB Ratio | 0.88 | |||||
Price-to-Tangible-Book | 0.78 | |||||
Price-to-Free-Cash-Flow | 15 | |||||
Price-to-Operating-Cash-Flow | 15 | |||||
EV-to-EBIT | -1.04 | |||||
EV-to-EBITDA | -1.04 | |||||
EV-to-FCF | 51.38 | |||||
Price-to-Graham-Number | 0.37 | |||||
Earnings Yield (Greenblatt) % | -96.15 | |||||
FCF Yield % | 2.06 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:BICTF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Biocure Technology Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | |||
EPS (TTM) ($) | -0.008 | ||
Beta | 0.57 | ||
Volatility % | 156.28 | ||
14-Day RSI | 0 | ||
14-Day ATR ($) | 0.000007 | ||
20-Day SMA ($) | 0.07 | ||
12-1 Month Momentum % | 363.58 | ||
52-Week Range ($) | 0.0151 - 0.07 | ||
Shares Outstanding (Mil) | 94 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Biocure Technology Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Biocure Technology Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Biocure Technology Inc Frequently Asked Questions
What is Biocure Technology Inc(BICTF)'s stock price today?
The current price of BICTF is $0.07. The 52 week high of BICTF is $0.07 and 52 week low is $0.02.
When is next earnings date of Biocure Technology Inc(BICTF)?
The next earnings date of Biocure Technology Inc(BICTF) is .
Does Biocure Technology Inc(BICTF) pay dividends? If so, how much?
Biocure Technology Inc(BICTF) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |